<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD), the effect of anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-Î±) antibody therapy on postoperative complications remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine the effects of infliximab on postoperative complication rates in patients undergoing abdominal surgery for CD </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Infliximab-treated CD patients undergoing abdominal surgery were identified in a prospective database </plain></SENT>
<SENT sid="3" pm="."><plain>Gender- and age-matched CD patients without infliximab treatment served as controls </plain></SENT>
<SENT sid="4" pm="."><plain>General and complication-related information was retrieved from patient records </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Forty-eight patients underwent abdominal surgery within 3 months (median 60 days, range 1-90 days) after infliximab administration (56% female, median age 35 years, range 17-66 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-eight patients without infliximab served as controls (50% female, 39 [17-68] years) </plain></SENT>
<SENT sid="7" pm="."><plain>Patient characteristics and number of minor complications were comparable between groups: wound <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (infliximab: 19% vs. controls: 15%), prolonged postoperative <z:hpo ids='HP_0002595'>ileus</z:hpo> (15% vs. 4%), and <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo> (2% vs. 0%; <z:hpo ids='HP_0000001'>all</z:hpo> P &gt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>No differences were found in major complications: anastomotic leakage (infliximab: 4% vs. controls: 13%), <z:mpath ids='MPATH_612'>abscess</z:mpath> formation (6% vs. 10%), bowel <z:mpath ids='MPATH_81'>perforation</z:mpath> (2% vs. 4%), stoma complication (6% vs. 2%), postoperative <z:mp ids='MP_0001914'>hemorrhage</z:mp> (8% vs. 2%), and enterocutaneous <z:mpath ids='MPATH_70'>fistula</z:mpath> (4% vs. 0%; <z:hpo ids='HP_0000001'>all</z:hpo> P &gt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>One malnourished infliximab-treated patient with a complicated course of disease died postoperatively after anastomotic leakage, <z:hpo ids='HP_0100806'>sepsis</z:hpo>, and <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Eleven infliximab and 10 control patients required reoperation (P &gt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>Hospital stay was comparable between groups (infliximab: 13 [5-41] vs. controls: 12 [5-54] days; P &gt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Infliximab does not affect postoperative complication rates, suggesting no need to alter surgical management in these patients </plain></SENT>
</text></document>